Anna French

Director at Jasper Therapeutics

Dr. French is a Partner at Qiming Venture Partners USA, where she invests in biotech and digital health companies, focusing on advanced therapeutics including cell and gene therapy. Her active investments include Jasper Therapeutics, WindMIL Therapeutics, Talaris Therapeutics, Cadent Therapeutics, LetsGetChecked and Platelet Biogenesis, for which she serves as a board observer. Previously, Dr. French was a Management Consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations, with an emphasis on cell and gene therapy. She also led a global industry/academic consortium focused on cell therapy commercialization. Dr. French earned a D.Phil. from the University of Oxford, UK, where her research focused on the hematopoietic differentiation of human induced pluripotent stem cells. She has over 20 publications in the field of stem cell research.


  • Director

    Current role


By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.